Author Archives: Joana Carvalho

Dry Powder Inhalers OK Despite Less Respiratory Muscle Strength

Despite having lower respiratory muscle strength, people with pulmonary arterial hypertension (PAH) can still use dry powder inhalers that require breath-actuated force to effectively deliver inhaled therapies, a study has found. The study, “Impact of human behavior on inspiratory flow profiles in patients with pulmonary arterial…

Insmed Announces Top-line Results from Phase 1 Trial of TPIP

Top-line data from a Phase 1 clinical trial has found that treprostinil palmitil inhalation powder (TPIP) — a dry powder form of a treprostinil precursor that is being developed by Insmed for treating pulmonary arterial hypertension (PAH) — was safe and well-tolerated in healthy volunteers. Results also showed…

FDA Approves Alembic’s Generic Injection of Remodulin for PAH

The U.S. Food and Drug Administration (FDA) has approved Alembic Pharmaceuticals’ injectable formulation of treprostinil, a generic version of Remodulin, to treat patients with pulmonary arterial hypertension (PAH), the company announced. Like the branded product, this generic version of United Therapeutics’ treprostinil will be available in multiple-dose vials…

UK Adults With PH Urged to Assess Self-help Program for Anxiety

The Pulmonary Hypertension Association U.K. (PHA UK), a charity organization dedicated to supporting those with pulmonary hypertension (PH), is urging adults with PH to participate in a research study assessing the usefulness of a self-help program to manage anxiety. By participating in the study patients will have…

Moderna, Chiesi Will Collaborate on New RNA-based Therapies for PAH

Moderna has entered a collaboration agreement with Chiesi Farmaceutici to develop new messenger RNA-based therapies for pulmonary arterial hypertension (PAH). Messenger RNAs (mRNAs) are the molecules that cells use as a template to make proteins; specifically, mRNAs carry the genetic code from DNA to the protein-making…